促红细胞生成素治疗蛛网膜下腔出血：综述。
Erythropoietin for the treatment of subarachnoid hemorrhage: a review.
机构信息
Department of Neurological Surgery, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, New Jersey, USA.
出版信息
World Neurosurg. 2010 May;73(5):500-7. doi: 10.1016/j.wneu.2010.02.026.
OBJECTIVE
Subarachnoid hemorrhage (SAH) has a worldwide incidence of approximately 10.5 cases per 100,000 person-years and constitutes 3% of all strokes. Erythropoietin (EPO) has recently been proposed for the treatment of a variety of brain diseases, including SAH, because of its neuroprotective effects. Hence, the current evidence in the published literature was reviewed to determine the potential utility of EPO in the treatment of SAH.
METHODS
A careful retrospective review of the literature was performed to determine the potential benefit of employing EPO in the treatment of SAH and its sequelae.
RESULTS
Careful literature review revelaed that the use of EPO may not necessarily reduce the incidence of vasospasm after SAH, but it may reduce the severity and its eventual outcome.
CONCLUSION
Given the recent trial results, a dose-escalation study and subsequent randomized trial should be considered.
目的
蛛网膜下腔出血（SAH）的全球发病率约为每 10 万人年 10.5 例，占所有中风的 3%。促红细胞生成素（EPO）由于其神经保护作用，最近被提议用于治疗各种脑部疾病，包括 SAH。因此，对已发表文献中的现有证据进行了审查，以确定 EPO 在治疗 SAH 中的潜在效用。
方法
仔细回顾文献，以确定在治疗 SAH 及其后遗症中使用 EPO 的潜在益处。
结果
仔细的文献回顾表明，使用 EPO 不一定能降低 SAH 后血管痉挛的发生率，但可能会降低其严重程度和最终结果。
结论
鉴于最近的试验结果，应考虑进行剂量递增研究和随后的随机试验。
Zotero 插件